RESEARCH TRIANGLE PARK, NC--(Marketwire - June 25, 2008) - Nearly three-quarters of business
development groups at surveyed pharmaceutical companies report having a
department that is centralized on the global level, concludes a new study
by pharmaceutical intelligence leader Cutting Edge Information. According
to the new study, other companies break business development (BD) personnel
up by therapeutic area, brand or geographic area
(
www.PharmaDealMaking.com).
In fact, business development and licensing representatives are often
combined into one globalized department, BD&L. According to Cutting Edge
Information's research, companies that have globalized departments find it
easier to manage a multitude of projects efficiently. Although dividing
the BD group into specialized business units carries its own set of
benefits, centralized departments are better equipped to track leads and
evaluate opportunities on a large scale. Centralization of the BD function
also prevents disparate units from competing with each other for deal
approvals and resources, and instead places the focus on determining which
deals offer the most value to the company.
"The fact is, companies that centralize their BD functions have an easier
time keeping track of all the partnership opportunities out there," says
Eric Bolesh, lead author of the study. "Some of these companies have
hundreds of leads to sift through, and a centralized structure allows
companies to place priority on the most promising candidates."
The 174-page report covers every aspect of BD management. It enables
companies to build a first-rate BD function and to facilitate the steps
leading toward closing a deal. Developed from surveys and interviews with
executives at leading pharmaceutical and biotechnology companies, the
report shows BD teams how to overcome challenges, align partnership
objectives, improve relationship-building, and drive the deal to
completion.
The report contains more than 400 metrics and benchmarks, including the
following:
-- Business development team headcounts
-- Business development team budgets
-- Cross-functional involvement in evaluation of new deals
-- Deal-making process timelines
-- Stages of development and marketing during which companies close
inbound and outbound deals
-- Royalty levels
-- Business development reporting structures
-- Deal warning signs
-- Best practices for each stage of the deal-making process
A summary of the report is available for immediate download here:
http://www.cuttingedgeinfo.com/pharmadealmaking/PH118_Download.asp#body.
Contact Information: CONTACT INFORMATION:
Eric Bolesh
at
or 919-433-0209